Targeted Delivery of VEGF to Treat Myocardial Infarction
Noninvasive injection of pro-angiogenic compounds such as vascular endothelial growth factor (VEGF) has shown promising results in regenerating cardiac microvasculature. However, these results have failed to translate into successful clinical trials in part due to the short half-life of VEGF in circulation. Increasing the dose of VEGF may increase its availability to the target tissue, but harmful side-effects remain a concern. Encapsulating and selectively targeting VEGF to the MI border zone may circumvent these problems. Anti-P-selectin conjugated immunoliposomes containing VEGF were developed to target the infarct border zone in a rat MI model. Targeted VEGF therapy significantly improves vascularization and cardiac function after an infarction.
KeywordsTargeted drug delivery Pro-angiogenic compounds Vasculature Cardiac function Myocardial infarction
This work was supported by grants from The American Heart Association, and The National Heart, Lung and Blood Institute. The human VEGF165A was generously provided by Genentech, Inc., San Francisco, CA.